Showing results (121-130 of 1,337) with videos related to

Sort By:
Pageof 134
Neuro-Oncology Advances|July 10, 2020
Proteins inform survival-based differences in patients with glioblastomaL C Stetson, Quinn T Ostrom, Daniela Schlatzer, et al.
Neuro-Oncology Advances|July 10, 2020
Circulating angiogenic cells in glioblastoma: toward defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularizationKarin Huizer, Andrea Sacchetti, Sigrid Swagemakers, et al.
Neuro-Oncology Advances|July 10, 2020
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1Mahmoud S Alghamri, Rohit Thalla, Ruthvik P Avvari, et al.
Neuro-Oncology Advances|July 10, 2020
MicroRNA-93 acts as an "anti-inflammatory tumor suppressor" in glioblastomaMax Hübner, Nicholas Moellhoff, David Effinger, et al.
Neuro-Oncology Advances|July 10, 2020
MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironmentYu-Ting Su, Madison Butler, Meili Zhang, et al.
Neuro-Oncology Advances|July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Neuro-Oncology Advances|July 10, 2020
TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumorsDiana Cantero, Manuela Mollejo, Juan M Sepúlveda, et al.
Neuro-Oncology Advances|July 10, 2020
After Nf1 loss in Schwann cells, inflammation drives neurofibroma formationJonathan S Fletcher, Jay Pundavela, Nancy Ratner
Neuro-Oncology Advances|July 10, 2020
Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1Abigail Godec, Reyka Jayasinghe, John S A Chrisinger, et al.
Neuro-Oncology Advances|July 16, 2020
Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade gliomaStephanie Vairy, Gwénaël Le Teuff, Francisco Bautista, et al.
Pageof 134